- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01193595
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
An Open-label, Non-randomized, Dose Escalation, Safety and Pharmacokinetic Phase I Study of Ombrabulin (AVE8062) in Combination With Bevacizumab Administered by Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.
Primary Objective:
- To determine the maximum administered dose (MAD) and the maximum tolerated dose (MTD) of ombrabulin in combination with best tolerated dose of bevacizumab based on the incidence of related Dose Limiting Toxicities (DLTs).
Secondary Objectives:
- To assess the overall safety profile of the combination
- To characterize the pharmacokinetic (PK) profile of both ombrabulin and bevacizumab when given in combination
- To evaluate preliminary evidence of anti-tumor activity
- To assess the pharmacodynamic effect using (Dynamic Contrast Enhanced Ultra-Sound) DCE-US, measuring biomarkers
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Sutton, Det Forenede Kongerige, SM2 5PT
- Investigational Site Number 826001
-
-
-
-
-
Villejuif Cedex, Frankrig, 94805
- Investigational Site Number 250001
-
-
-
-
-
Milano, Italien, 20133
- Investigational Site Number 380001
-
Milano, Italien, 20132
- Investigational Site Number 380002
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
- Histologically or cytologically proven solid malignant tumor at the first diagnosis with the exception of squamous non small cell lung cancer (NSCLC).
- Advanced neoplastic disease (i.e. metastatic or locally unresectable advanced disease)
- Presence of one measurable lesion at baseline in the MTD expanded cohort
Exclusion criteria:
- ECOG (Eastern cooperativeOncology Group) performance status > 1
- Concurrent treatment with any other anticancer therapy
- Pericardial effusion requiring intervention (drainage)
- History of brain metastasis, spinal cord compression or carcinomatous meningitis or new evidence of brain metastasis on screening Computed tomography (CT) or Magnetic resonance imaging (MRI) scan
- Diagnosis of squamous Non Squamous Cell Lung Cancer (NSCLC) or with mixed cell type with predominant squamocellular histology
- Hormone sensitive prostate cancer
- Abdominal Radiotherapy
- Major surgery within the last month of study enrollment or surgical wound not fully healed before study enrollment
- High cumulative doses of anthracycline
- Inadequate organ function
- Inadequate hematology function or poor bone marrow reserve
- Any of the following within 6 months prior to study enrollment: peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease and diverticulitis
- Any history or underlying cardiac condition that may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: AVE8062/ bevacizumab
The combination of ombrabulin and bevacizumab will be administered every 3 weeks according to the following schedule: One day 1, ombrabulin will be administered as a 30 minutes intravenous (i.v) infusion.
Bevacizumab will be administered as a 30-90 minutes i.v.
infusion 24 hours after the end of ombrabulin infusion on day 2.
|
Pharmaceutical form:Solution for infusion Route of administration: Intravenous Pharmaceutical form:Solution for infusion Route of administration: Intravenous |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Incidence of Dose Limiting Toxicities (DLTs) that will define the MTD
Tidsramme: 3 weeks
|
3 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Overall safety profile of the combination
Tidsramme: up to a maximum follow-up of 1 year
|
up to a maximum follow-up of 1 year
|
Pharmacokinetic parameters of ombrabulin
Tidsramme: 6 weeks
|
6 weeks
|
Pharmacokinetic parameters of bevacizumab
Tidsramme: 6 weeks
|
6 weeks
|
Preliminary evidence of antitumor activity according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Tidsramme: up to a maximum follow-up of 1 year
|
up to a maximum follow-up of 1 year
|
Pharmacodynamic effect (biomarkers)
Tidsramme: cycle 1
|
cycle 1
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- TCD11379
- 2009-017797-20 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Neoplasmer, ondartede
-
Guangzhou First People's HospitalAfsluttet
-
Aveni FoundationLedigSarkom | Blødt vævssarkom | Kræft i bugspytkirtlen | Osteosarkom | Kondrosarkom | Chordoma | Carcinom i brystet | MPNST (Malignant Perifer Nerve Skede Tumor)Forenede Stater
Kliniske forsøg med Ombrabulin (AVE8062)
-
SanofiAfsluttet
-
SanofiAfsluttetNeoplasmerFrankrig, Italien, Schweiz
-
SanofiAfsluttetSarkomBelgien, Ungarn, Forenede Stater, Brasilien, Frankrig, Indien, Italien, Serbien, Spanien, Det Forenede Kongerige
-
SanofiAfsluttet
-
SanofiAfsluttetIkke-småcellet lungekræftFrankrig, Rumænien, Polen, Kroatien, Korea, Republikken, Italien, Chile, Forenede Stater, Australien, Tyskland, Den Russiske Føderation, Serbien, Ukraine
-
SanofiAfsluttet
-
SanofiAfsluttet
-
SanofiAfsluttet
-
SanofiAfsluttetAvancerede solide tumorerJapan
-
SanofiAfsluttetOvariekræft TilbagevendendeBelgien, Den Russiske Føderation, Polen, Spanien, Tjekkiet, Forenede Stater, Frankrig, Tyskland, Italien, Ukraine